Nuvation Bio (NUVB) just unveiled an announcement.
Nuvation Bio Inc. recently completed its acquisition of AnHeart Therapeutics, issuing numerous shares and warrants to AnHeart’s securityholders. This strategic move significantly diversifies ownership, with former AnHeart shareholders now owning about one-third of Nuvation Bio’s stock. Moreover, the deal led to the appointment of two new directors to Nuvation Bio’s board, bringing valuable industry experience from their previous leadership roles. These developments, exempt from registration under the Securities Act, signify a notable expansion and leadership change for the growing biotech firm.
See more data about NUVB stock on TipRanks’ Stock Analysis page.
